UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, DC 20549 

FORM 8-K 

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(d) OF THE 

SECURITIES EXCHANGE ACT OF 1934 

Date of Report (Date of earliest event reported): February 14, 2019 

BOSTON SCIENTIFIC CORPORATION 

(Exact name of registrant as specified in its charter) 

  [DATA_TABLE_REMOVED] 

300 Boston Scientific Way, Marlborough, 

Massachusetts       01752-1234   

  (Address of principal executive offices)       (Zip code)    

Registrant’s telephone number, including area code: (508) 683-4000 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 8.01 Other Events. 

On February 14, 2019, each of Boston Scientific Corporation (the “Company”) and BTG plc (“BTG”) received a request for additional information and documentary material from the United States Federal Trade Commission in connection with the recommended cash offer to acquire the entire issued and to be issued ordinary share capital of BTG by Bravo Bidco Limited, a newly incorporated indirect wholly-owned subsidiary of the Company (the “Acquisition”). 

A copy of the joint announcement dated February 15, 2019, made by the Company and BTG with respect to this request on the London-based Regulatory News Service (“RNS”) is attached as Exhibit 99.1 and is incorporated herein by reference. 

 Item 9.01   Financial Statements and Exhibits     

(d) Exhibits

  Exhibit No.     Description   

  Exhibit 99.1     RNS Announcement of Boston Scientific Corporation and BTG plc, dated February 15, 2019.    

Further Information 

This Form 8-K is not intended to and does not constitute or form part of any offer to sell or subscribe for or any invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Acquisition or otherwise nor will there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable laws. The Acquisition will be implemented pursuant to the terms of the document sent to shareholders of BTG on January 24, 2019, which sets out the full details of the court-sanctioned scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006, as amended (the “Scheme Document”), and contains the full terms and conditions of the Acquisition, including details of how to vote in respect of the Acquisition. Any decision in respect of, or other response to, the Acquisition should be made only on the basis of the information contained in the Scheme Document. 

SIGNATURE 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED]